Oral glycoprotein IIb/IIIa inhibition - Great idea, but it didn't work

American Journal of Medicine

Volumn 112, Issue 8, 2002, Pages 673-675

  Cannon, Christopher P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CD63 ANTIGEN; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORBOFIBAN; PADGEM PROTEIN; RECEPTOR BLOCKING AGENT; TIROFIBAN; UNCLASSIFIED DRUG;

APOPTOSIS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 0036605924     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01146-4     Document Type: Editorial

References (24)

1. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials
2. Randomised placebo-controlled and balloon-angioplasty-controlled trail to assess the safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
3. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
4. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
6. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
7. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
8. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
9. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
10. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
11. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
12. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists
13. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial
14. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention
15. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from PURSUIT
16. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
18. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions
19. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy
20. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil-platelet interactions in patients with acute coronary syndromes
21. 3 ) inhibitors
22. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
23. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation